Jaskuła Emilia, Lange Janusz, Sędzimirska Mariola, Suchnicki Krzysztof, Mordak-Domagała Monika, Pakos Helena, Lange Andrzej
L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland; Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry, Wroclaw, Poland.
Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry, Wroclaw, Poland.
Transpl Immunol. 2021 Apr;65:101370. doi: 10.1016/j.trim.2021.101370. Epub 2021 Jan 20.
Cytokine storm described in patients after allogeneic haematopoietic stem cell transplantation (alloHSCT) is associated with the appearance of CD14 + HLADR - in the blood.
To study the role of CD14 + HLADR - cells 223 patients after alloHSCT followed from 1 month to 15 years. The methods used included flow cytometry for blood cells profiling, nucleic acid tests for viral reactivation, and physician care according to the Polish and international guidelines.
We found that CD14 + HLADR - peak values determined during the first 60 post-transplant days were higher in the patients who died than in those who survived in this time interval (mean ± SEM: 3.78 ± 0.67% vs 2.38 ± 0.65%, p < 0.001). Receiver operating characteristic (ROC) analysis showed that CD14 + HLADR - cells level in the blood at cut-off point at 0.71% discriminated the patients as to survival; the patients above the threshold had poorer survival (Kaplan-Meier curve covering 15-year observation) than those below (0.19 vs 0.46, p < 0.001). Infections prevailed other causes of death in the high blood CD14 + HLADR - group (0.61 vs 0.38, p = 0.057). ROC analysis defined the CD4+ blood level at 17.70% as not significantly associated with survival. Multivariate analysis revealed that CD14 + HLADR - cells (HR = 3.47, p < 0.001) and the presence of acute graft-versus-host disease (aGvHD) grade ≥ 3 (HR = 3.82, p = 0.005) adversely impacted the survival.
CD14 + HLADR - cells can serve as a biomarker for the risk of fatal complications frequently associated with infections.
异基因造血干细胞移植(alloHSCT)后患者中描述的细胞因子风暴与血液中CD14 + HLA-DR - 的出现有关。
为研究CD14 + HLA-DR - 细胞的作用,对223例alloHSCT后的患者进行了1个月至15年的随访。使用的方法包括血细胞分析的流式细胞术、病毒再激活的核酸检测以及根据波兰和国际指南的医生护理。
我们发现,移植后前60天内测定的CD14 + HLA-DR - 峰值在死亡患者中高于在此时间间隔内存活的患者(平均值±标准误:3.78±0.67%对2.38±0.65%,p<0.001)。受试者工作特征(ROC)分析表明,血液中CD14 + HLA-DR - 细胞水平在临界点为0.71%时可区分患者的生存情况;高于阈值的患者生存情况较差(覆盖15年观察期的Kaplan-Meier曲线),低于阈值的患者生存情况较好(0.19对0.46,p<0.001)。在血液CD14 + HLA-DR - 高水平组中,感染是死亡的主要原因,而非其他原因(0.61对0.38,p = 0.057)。ROC分析确定血液中CD4 + 水平为17.70%与生存无显著相关性。多变量分析显示,CD14 + HLA-DR - 细胞(风险比=3.47,p<0.001)和急性移植物抗宿主病(aGvHD)≥3级的存在(风险比=3.82,p = 0.005)对生存有不利影响。
CD14 + HLA-DR - 细胞可作为与感染相关的致命并发症风险的生物标志物。